Osteologix, Inc. has received a key U.S. Patent Allowance for its osteoporosis drug, NB S101 (strontium malonate). This brings the company closer to its goal of manufacturing and marketing a prescription strontium drug in the U.S.
The Notice of Allowance from the U.S. Patent and Trademark Office is for U.S. Patent Application Number 11/269,289 titled "Water-Soluble Strontium Salts for Use in Treatment of Cartilage and/or Bone Conditions." It allows claims covering the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate). The patent will most likely issue in the second half of 2009 and expire in 2024.





Add to the discussion